# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Raymond James analyst Chris Raymond initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Strong Buy rating and an...